Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Overall survival, post-surgery chemotherapy vs surgery alone (no radiotherapy) · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Surgery +/- radiotherapy + (adjuvant) chemotherapy showed no clear difference in overall survival, adjuvant chemotherapy vs observation alone… compared with surgery +/- radiotherapy alone (observation or adjuvant radiotherapy… (moderate certainty).
1 finding from 1 review
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
2 findings from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy probably leads to lower premature ovarian failure compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in pregnancy compared with chemotherapy alone (low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher ovulation compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist plus chemotherapy changes adverse effects: hot flush compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to surgery vs surgery alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (low certainty).
1 finding from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to radiotherapy vs radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (moderate certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… led to lower disease-free survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone; GRADE not reported.
1 finding from 1 review
Complete response · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 6.54 [1, 42.86]
36 participants
Very low
Complete response plus partial response Length of · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.47 [0.87, 2.49]
36 participants
Very low